Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eliglustat + immune checkpoint inhibitor
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy that pairs eliglustat, a glucosylceramide synthase inhibitor, with immune checkpoint inhibitors. Eliglustat inhibits glycosphingolipid synthesis, which increases the exposure of major histocompatibility complex (MHC) and tumor antigen peptides, enhancing the antitumor response of CD8+ T cells. This mechanism complements immune checkpoint inhibitors, which block proteins like PD-1 that normally prevent T cells from attacking cancer cells. The combination has shown promising results in clinical trials for advanced cancers, particularly for proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer.
- Other names
- eliglustat + anti-PD-1GSL synthetase inhibitor + immune checkpoint inhibitor
02
Targets
UGCG (UDP-glucose ceramide glucosyltransferase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on eliglustat + immune checkpoint inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eliglustat + immune checkpoint inhibitor.